We treated MOG-G-UVW, U-251, and SF-188 (EV and ATRX KO) high-grade glioma cell lines with different concentrations (5 μM and 10 μM) of BTK, STAT3, and RTK inhibitors for 48 h in order to assess cell viability. This evidence concerns the gene BTK and central nervous system cancer.